The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth

Journal of Immunology

Volumn 184, Issue 1, 2010, Pages 369-378

  Büchau, Amanda S ^a,c,d   Morizane, Shin ^a,c,d   Trowbridge, Janet ^a,c,d,e,f   Schauber, Jürgen ^a,c,d   Kotol, Paul ^a,c,d   Bui, Jack D ^b   Gallo, Richard L ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Northwest Dermatology and Skin Cancer Clinic   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN; INTERLEUKIN 2; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE BINDING PROTEIN; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HOST RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KNOCKOUT MOUSE; MICROENVIRONMENT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRAIN DIFFERENCE; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; DRUG SCREENING; EXPERIMENTAL MELANOMA; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; IMMUNOSURVEILLANCE; MASS SPECTROMETRY; MOUSE MUTANT; WESTERN BLOTTING;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOTTING, WESTERN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73949092172     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902110     Document Type: Article

References (68)

1. Bui, J. D., and R. D. Schreiber. 2007. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 19: 203-208.
2. Yadav, D., J. Ngolab, R. S. Lim, S. Krishnamurthy, and J. D. Bui. 2009. Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFNγ-induced microRNA. J. Immunol. 182: 39-43.
3. Smyth, M. J., J. Swann, and Y. Hayakawa. 2007. Innate tumor immune surveillance. Adv. Exp. Med. Biol. 590: 103-111.
4. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
5. Watzl, C., and E. O. Long. 2000. Exposing tumor cells to killer cell attack. Nat. Med. 6: 867-868.
6. Smyth, M. J., D. I. Godfrey, and J. A. Trapani. 2001. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2: 293-299.
7. Hayakawa, Y., J. M. Kelly, J. A. Westwood, P. K. Darcy, A. Diefenbach, D. Raulet, and M. J. Smyth. 2002. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J. Immunol. 169: 5377-5381.
8. Poeck, H., R. Besch, C. Maihoefer, M. Renn, D. Tormo, S. S. Morskaya, S. Kirschnek, E. Gaffal, J. Landsberg, J. Hellmuth, et al. 2008. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14: 1256-1263.
9. Lakshmikanth, T., S. Burke, T. H. Ali, S. Kimpfler, F. Ursini, L. Ruggeri, M. Capanni, V. Umansky, A. Paschen, A. Sucker, et al. 2009. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119: 1251-1263.
10. Trapani, J. A., and M. J. Smyth. 2002. Functional significance of the perforin/ granzyme cell death pathway. Nat. Rev. Immunol. 2: 735-747.
11. van den Broek, M. F., D. Kägi, R. M. Zinkernagel, and H. Hengartner. 1995. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol. 25: 3514-3516.
12. van den Broek, M. E., D. Kägi, F. Ossendorp, R. Toes, S. Vamvakas, W. K. Lutz, C. J. Melief, R. M. Zinkernagel, and H. Hengartner. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184: 1781-1790.
13. Zanetti, M. 2005. The role of cathelicidins in the innate host defenses of mammals. Curr. Issues Mol. Biol. 7: 179-196.
14. Gudmundsson, G. H., B. Agerberth, J. Odeberg, T. Bergman, B. Olsson, and R. Salcedo. 1996. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem. 238: 325-332.
15. Gallo, R. L., K. J. Kim, M. Bernfield, C. A. Kozak, M. Zanetti, L. Merluzzi, and R. Gennaro. 1997. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J. Biol. Chem. 272: 13088-13093.
16. Chromek, M., Z. Slamová, P. Bergman, L. Kovács, L. Podracká, I. Ehrén, T. Hökfelt, G. H. Gudmundsson, R. L. Gallo, B. Agerberth, and A. Brauner. 2006. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 12: 636-641.
17. Howell, M. D., A. Wollenberg, R. L. Gallo, M. Flaig, J. E. Streib, C. Wong, T. Pavicic, M. Boguniewicz, and D. Y. Leung. 2006. Cathelicidin deficiency predisposes to eczema herpeticum. J. Allergy Clin. Immunol. 117: 836-841.
18. Nizet, V., T. Ohtake, X. Lauth, J. Trowbridge, J. Rudisill, R. A. Dorschner, V. Pestonjamasp, J. Piraino, K. Huttner, and R. L. Gallo. 2001. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414: 454-457.
19. Rosenberger, C. M., R. L. Gallo, and B. B. Finlay. 2004. Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular Salmonella replication. Proc. Natl. Acad. Sci. USA 101: 2422-2427.
20. Iimura, M., R. L. Gallo, K. Hase, Y. Miyamoto, L. Eckmann, and M. F. Kagnoff. 2005. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J. Immunol. 174: 4901-4907. (Pubitemid 40504574)
21. Chuang, C. M., A. Monie, A. Wu, C. P. Mao, and C. F. Hung. 2009. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum. Gene Ther. 20: 303-313.
22. Coffelt, S. B., F. C. Marini, K. Watson, K. J. Zwezdaryk, J. L. Dembinski, H. L. LaMarca, S. L. Tomchuck, K. Honer zu Bentrup, E. S. Danka, S. L. Henkle, and A. B. Scandurro. 2009. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc. Natl. Acad. Sci. USA 106: 3806-3811.
23. Coffelt, S. B., R. S. Waterman, L. Florez, K. Höner zu Bentrup, K. J. Zwezdaryk, S. L. Tomchuck, H. L. LaMarca, E. S. Danka, C. A. Morris, and A. B. Scandurro. 2008. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int. J. Cancer 122: 1030-1039.
24. Agerberth, B., J. Charo, J. Werr, B. Olsson, F. Idali, L. Lindbom, R. Kiessling, H. Jörnvall, H. Wigzell, and G. H. Gudmundsson. 2000. The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96: 3086-3093.
25. Gutsmann, T., S. O. Hagge, J. W. Larrick, U. Seydel, and A. Wiese. 2001. Interaction of CAP18-derived peptides with membranes made from endotoxins or phospholipids. Biophys. J. 80: 2935-2945. (Pubitemid 32521665)
26. Kärre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678. (Pubitemid 16119452)
27. Kiessling, R., E. Klein, and H. Wigzell. 1975. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells: specificity and distribution according to genotype. Eur. J. Immunol. 5: 112-117.
28. Dorschner, R. A., V. K. Pestonjamasp, S. Tamakuwala, T. Ohtake, J. Rudisill, V. Nizet, B. Agerberth, G. H. Gudmundsson, and R. L. Gallo. 2001. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 117: 91-97.
29. + T cell immunity. Nat. Immunol. 7: 1317-1325.
30. Schauber, J., R. A. Dorschner, K. Yamasaki, B. Brouha, and R. L. Gallo. 2006. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 118: 509-519 .
31. Di Nardo, A., K. Yamasaki, R. A. Dorschner, Y. Lai, and R. L. Gallo. 2008. Mast cell cathelicidin antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. J. Immunol. 180: 7565-7573.
32. Chang, L., G. A. Gusewitch, D. B. Chritton, J. C. Folz, L. K. Lebeck, and S. L. Nehlsen-Cannarella. 1993. Rapid flow cytometric assay for the assessment of natural killer cell activity. J. Immunol. Methods 166: 45-54.
33. Goldberg, J. E., S. W. Sherwood, and C. Clayberger. 1999. A novel method for measuring CTL and NK cell-mediated cytotoxicity using annexin V and twocolor flow cytometry. J. Immunol. Methods 224: 1-9.
34. Grossman, W. J., J. W. Verbsky, B. L. Tollefsen, C. Kemper, J. P. Atkinson, and T. J. Ley. 2004. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104: 2840-2848.
35. Kane, K. L., F. A. Ashton, J. L. Schmitz, and J. D. Folds. 1996. Determination of natural killer cell function by flow cytometry. Clin. Diagn. Lab. Immunol. 3: 295-300.
36. Büchau, A. S., and R. L. Gallo. 2007. Innate immunity and antimicrobial defense systems in psoriasis. Clin. Dermatol. 25: 616-624.
37. Schauber, J., R. A. Dorschner, A. B. Coda, A. S. Büchau, P. T. Liu, D. Kiken, Y. R. Helfrich, S. Kang, H. Z. Elalieh, A. Steinmeyer, et al. 2007. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 117: 803-811.
38. + cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol. Immunother. 58: 575-587.
39. Diefenbach, A., E. R. Jensen, A. M. Jamieson, and D. H. Raulet. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171.
40. Kim, S., K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama. 2000. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA 97: 2731-2736.
41. Aguiló, J. I., J. Garaude, J. Pardo, M. Villalba, and A. Anel. 2009. Protein kinase C-θ is required for NK cell activation and in vivo control of tumor progression. J. Immunol. 182: 1972-1981.
42. Kim, S., K. Iizuka, H. S. Kang, A. Dokun, A. R. French, S. Greco, and W. M. Yokoyama. 2002. In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol. 3: 523-528.
43. Piontek, G. E., K. Taniguchi, H. G. Ljunggren, A. Grönberg, R. Kiessling, G. Klein, and K. Kärre. 1985. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J. Immunol. 135: 4281-4288.
44. Chun, M., and M. K. Hoffmann. 1982. Modulation of interferon-induced NK cells by interleukin 2 and cAMP. Lymphokine Res. 1: 91-98.
45. Lotzová, E., and C. A. Savary. 1986. Interleukin-2 corrects defective NK activity of patients with leukemia. Comp. Immunol. Microbiol. Infect. Dis. 9: 169-175.
46. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
47. Dennison, S. R., F. Harris, and D. A. Phoenix. 2007. The interactions of aurein 1.2 with cancer cell membranes. Biophys. Chem. 127: 78-83.
48. Ohsaki, Y., A. F. Gazdar, H. C. Chen, and B. E. Johnson. 1992. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res. 52: 3534-3538.
49. Okumura, K., A. Itoh, E. Isogai, K. Hirose, Y. Hosokawa, Y. Abiko, T. Shibata, M. Hirata, and H. Isogai. 2004. C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett. 212: 185-194.
50. Wong, J. H., and T. B. Ng. 2005. Sesquin, a potent defensin-like antimicrobial peptide from ground beans with inhibitory activities toward tumor cells and HIV- 1 reverse transcriptase. Peptides 26: 1120-1126.
51. Papo, N., and Y. Shai. 2003. New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 42: 9346-9354.
52. Coffelt, S. B., and A. B. Scandurro. 2008. Tumors sound the alarmin(s). Cancer Res. 68: 6482-6485.
53. Weber, G., C. I. Chamorro, F. Granath, A. Liljegren, S. Zreika, Z. Saidak, B. Sandstedt, S. Rotstein, R. Mentaverri, F. Sánchez, et al. 2009. Human anti-microbial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res. 11: R6.
54. De Yang, Q., A. P. Chen, G. M. Schmidt, J. M. Anderson, J. Wang, J. J. Wooters, Oppenheim, and O. Chertov. 2000. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192: 1069-1074.
55. Elssner, A., M. Duncan, M. Gavrilin, and M. D. Wewers. 2004. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 b processing and release. J. Immunol. 172: 4987-4994. (Pubitemid 38456425)
56. Koczulla, R., G. von Degenfeld, C. Kupatt, F. Krötz, S. Zahler, T. Gloe, K. Issbrücker, P. Unterberger, M. Zaiou, C. Lebherz, et al. 2003. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111: 1665-1672.
57. Kurosaka, K., Q. Chen, F. Yarovinsky, J. J. Oppenheim, and D. Yang. 2005. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. 174: 6257-6265.
58. Braff, M. H., A. Di Nardo, and R. L. Gallo. 2005. Keratinocytes store the anti-microbial peptide cathelicidin in lamellar bodies. J. Invest. Dermatol. 124: 394-400.
59. Di Nardo, A., M. H. Braff, K. R. Taylor, C. Na, R. D. Granstein, J. E. McInturff, S. Krutzik, R. L. Modlin, and R. L. Gallo. 2007. Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J. Immunol. 178: 1829-1834.
60. Pütsep, K., G. Carlsson, H. G. Boman, and M. Andersson. 2002. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360: 1144-1149.
61. Di Nardo, A., A. Vitiello, and R. L. Gallo. 2003. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170: 2274-2278. (Pubitemid 36245611)
62. Djeu, J. Y., J. A. Heinbaugh, H. T. Holden, and R. B. Herberman. 1979. Role of macrophages in the augementation of mouse natural killer cell activity by poly I: C and interferon. J. Immunol. 122: 182-188. (Pubitemid 9078538)
63. Djeu, J. Y., J. A. Heinbaugh, W. D. Vieira, H. T. Holden, and R. B. Herberman. 1979. The effect of immunopharmacological agents on mouse natural cell-mediated cytotoxicity and on its augmentation by poly I:C. Immunopharmacology 1: 231-244.
64. Schmidt, K. N., B. Leung, M. Kwong, K. A. Zarember, S. Satyal, T. A. Navas, F. Wang, and P. J. Godowski. 2004. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J. Immunol. 172: 138-143.
65. Lu, Q., A. Wu, D. Ray, C. Deng, J. Attwood, S. Hanash, M. Pipkin, M. Lichtenheld, and B. Richardson. 2003. DNA methylation and chromatin structure regulate T cell perforin gene expression. J. Immunol. 170: 5124-5132.
66. Pipkin, M. E., B. Ljutic, F. Cruz-Guilloty, M. Nouzova, A. Rao, J. C. Zúñiga-Pflücker, and M. G. Lichtenheld. 2007. Chromosome transfer activates and delineates a locus control region for perforin. Immunity 26: 29-41.
67. Wang, T.-T., F. P. Nestel, V. Bourdeau, Y. Nagai, Q. Wang, J. Liao, L. Tavera-Mendoza, R. Lin, J. W. Hanrahan, S. Mader, et al. 2004. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. [Published erratum appears in 2004 J. Immunol. 173: 6489.] J. Immunol. 173: 2909-2912.
68. Garland, C. F., E. D. Gorham, S. B. Mohr, and F. C. Garland. 2009. Vitamin D for cancer prevention: global perspective. Ann. Epidemiol. 19: 468-483